Hypertension, Impaired Liver Function, Preeclampsia, Proteinuria, Pulmonary Edema, Renal Insufficiency, Thrombocytopenia
Conditions
Keywords
Hypertension, Proteinuria, Thrombocytopenia, Renal Insufficiency, Impaired Liver Function, Pulmonary Edema
Brief summary
Preeclampsia (Pre-E) is a hypertensive disease of pregnancy with multi-system involvement that usually occurs in the second half of pregnancy. Pre-E occurs in 5% to 7% of U.S. pregnancies, and is the third-leading cause of U.S. maternal death. Improvements to the current diagnostic paradigm have been evaluated. However, no stand-alone diagnostic method has emerged that more accurately identifies women at risk for preeclampsia, warranting improvements in diagnosing Pre-E. This sample collection study will obtain serum and urine samples from pregnant women who present with clinical signs, symptoms, or conditions contributing to the suspicion of Pre-E. Samples will be used to evaluate and validate the performance of an assay intended to aid in assessing the risk of Pre-E.
Detailed description
Eligible subjects will provide written informed consent after which demographic and baseline clinical data will be recorded. Collection of whole blood and urine samples will be performed at one or more clinic visits from pregnant women carrying a single fetus with no known fetal abnormalities. Interim study visits will continue every 14 days \[+/- 3 days\] until the subject either: 1) reaches 37 0/7 weeks' gestation, 2) develops Pre-E, 3) delivers, or 4) is lost to follow-up. In addition, a group of pregnant women diagnosed with Pre-E will be enrolled as positive control cases.
Interventions
None listed
Sponsors
Progenity, Inc.
Study design
Observational model
FAMILY_BASED
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 45 Years
Healthy volunteers
No
Inclusion criteria
Eligibility criteria for the STUDY COHORT (CASES and NEGATIVE PRE-E CONTROLS): Inclusion Criteria: * Subject is willing to provide informed consent and comply with study procedures * 18 to 45 years of age * Singleton fetus of 28 0/7 to 36 6/7 weeks' gestational age using the 2014 American Congress of Obstetricians and Gynecologists (ACOG) Dating Criteria (pregnancies starting as twins but complicated with either vanishing twin syndrome or fetal demise of one twin before 14 weeks, are eligible for inclusion) * Patient presenting with clinical suspicion of Pre-E based on either: New onset elevated blood pressure in otherwise normotensive patient, worsening hypertension in a patient with pre-existing hypertension, new onset proteinuria or worsening of pre-existing proteinuria, or any other clinical finding requiring a workup to rule-out Pre-E.
Exclusion criteria
* Pregnancy is non-viable or absence of fetal cardiac activity * Diagnosis of Pre-E or anticipated delivery within 24 to 48 hours because of Pre-E with severe features including: persistent severe hypertension (systolic ≥160 or diastolic ≥110; thrombocytopenia \<100,000; liver enzymes 2x above upper normal limit or \>70 with severe persistent right upper quadrant (RUQ) or epigastric pain, new development of renal insufficiency; pulmonary edema; new-onset persistent cerebral or visual disturbances. * Major fetal anomaly or chromosomal aneuploidy * Current dialysis for kidney failure, including continuous ambulatory peritoneal dialysis Eligibility criteria for the POSITIVE CONTROL group: Inclusion Criteria: * Subject is willing to provide informed consent and comply with study procedures * 18 to 45 years of age * Singleton fetus of 28 0/7 to 36 6/7 weeks' gestational age using 2014 ACOG Dating Criteria (pregnancies starting as twins but complicated with either vanishing twin syndrome or fetal demise of one twin before 14 weeks, are eligible for inclusion) * Patient diagnosed with Pre-E using 2013 ACOG guidelines
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Suspected and Pre-E cases determined by institutional standards | about 2 years |
Countries
United States
Outcome results
None listed